Noa Krawczyk
Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
PhD, Mental Health, Johns Hopkins Bloomberg School of Public Health
BA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery.
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed


Krawczyk N, Bandara S, Merritt S, Shah H, Duncan A, McEntee B, Schiff M, Ahamd NJ, Whaley S, Latimore A, Saloner B (2022).
Jail-based treatment for opioid use disorder in the era of bail reform: A qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative
Addiction Science and Clinical Practice, 17, 30. doi: 10.1186/s13722-022-00313-6.

Tofighi B, McNeely J, Yang J, Thomas A, Schatz D, Reed T, Krawczyk N (2022).
Outcomes of a NYC public hospital system low-threshold tele-buprenorphine bridge clinic at 1 year
Substance Use and Misuse [Epub 2022 Apr 28]. doi: 10.1080/10826084.2022.2069269.

Samuels EA, Khatri UG, Snyder H, Wightman RS, Tofighi B, Krawczyk N (2022).
Buprenorphine telehealth treatment initiation and follow-up during COVID-19
Journal of General Internal Medicine, 37 (5), 1331-1333. doi: 10.1007/s11606-021-07249-8. PMCID: PMC8722662.

Bandara S, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, Saloner B, Krawczyk N (2022).
Opioid treatment program safety measures during the COVID-19 pandemic: A statewide survey
BMC Health Services Research, 22 (1), 418. doi: 10.1186/s12913-022-07832-7. PMCID: PMC8965537.

Arshonsky J, Krawczyk N, Bunting AM, Frank D, Friedman SR, Bragg MA (2022).
Informal coping strategies among people who use opioids during COVID-19: A thematic analysis of Reddit forums
JMIR Formative Research, 6 (3), e32871. doi: 10.2196/32871.


Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D (2019).
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.

Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.

Dr. Krawczyk's MyBibliography Profile
Selected Press